564818678	564818678	CD	B-NP	O
|	|	JJ	I-NP	O
T	T	NN	I-NP	O
|	|	VBD	B-VP	O
24805229	24805229	CD	B-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
0840530	0840530	CD	B-NP	O
|	|	CC	I-NP	O
6/20/2006	6/20/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
Musculoskeletal	Musculoskeletal	JJ	I-NP	I-protein
pain	pain	NN	I-NP	I-protein
|	|	NN	I-NP	I-protein
|	|	NN	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
1/30/2006	1/30/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
1/29/2006	1/29/2006	CD	B-NP	O
******	******	SYM	I-NP	O
FINAL	FINAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NN	I-NP	O
******	******	SYM	B-VP	O
TORNESE	TORNESE	NN	B-NP	O
,	,	,	O	O
EVERETT	EVERETT	NN	B-NP	O
229-95-96-2	229-95-96-2	CD	I-NP	O
none	none	NN	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
CAR	CAR	NN	B-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
PATIENT	PATIENT	NN	I-NP	O
ON	ON	NN	I-NP	O
:	:	:	O	O
8/19/06	8/19/06	CD	B-NP	O
AT	AT	NN	I-NP	O
01	01	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NNP	I-NP	O
CONTINGENT	CONTINGENT	NNP	I-NP	O
UPON	UPON	NNP	I-NP	O
Not	Not	NNP	I-NP	O
Applicable	Applicable	NNP	I-NP	O
WILL	WILL	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
VITEK	VITEK	NNP	B-NP	O
,	,	,	O	O
EMMETT	EMMETT	NNP	B-NP	O
W.	W.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
CODE	CODE	NNP	I-NP	O
STATUS	STATUS	NNP	I-NP	O
:	:	:	O	O
Full	Full	JJ	B-NP	O
code	code	NN	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
Home	Home	NN	B-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
AGGRENOX	AGGRENOX	NN	B-NP	O
-LRB-	-LRB-	SYM	B-NP	O
ASPIRIN	ASPIRIN	NN	I-NP	O
+	+	SYM	I-NP	O
DIPYRIDAMOLE	DIPYRIDAMOLE	NN	I-NP	O
-RRB-	-RRB-	SYM	B-NP	O
1	1	CD	I-NP	O
CAPSULE	CAPSULE	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
Override	Override	NNP	I-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
2/12/06	2/12/06	CD	B-NP	O
by	by	IN	B-PP	O
LUKA	LUKA	NNP	B-NP	O
,	,	,	O	O
HENRY	HENRY	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
WARFARIN	WARFARIN	NN	B-NP	O
SODIUM	SODIUM	NN	I-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
463914335	463914335	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
ASPIRIN	ASPIRIN	NNP	B-NP	O
&	&	CC	I-NP	O
WARFARIN	WARFARIN	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
ok	ok	VB	B-VP	O
Number	Number	NNP	B-NP	O
of	of	IN	B-PP	O
Doses	Doses	NNP	B-NP	O
Required	Required	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
10	10	CD	B-NP	O
ENTERIC	ENTERIC	NNP	I-NP	O
COATED	COATED	NNP	I-NP	O
ASPIRIN	ASPIRIN	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ASPIRIN	ASPIRIN	NNP	I-NP	O
ENTERIC	ENTERIC	NNP	I-NP	O
COATED	COATED	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
81	81	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Override	Override	NNP	I-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
2/12/06	2/12/06	CD	B-NP	O
by	by	IN	B-PP	O
UDE	UDE	NNP	B-NP	O
,	,	,	O	O
LINDSAY	LINDSAY	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
WARFARIN	WARFARIN	NN	B-NP	O
SODIUM	SODIUM	NN	I-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
463914335	463914335	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
ASPIRIN	ASPIRIN	NNP	B-NP	O
&	&	CC	I-NP	O
WARFARIN	WARFARIN	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
ok	ok	VB	B-VP	O
LIPITOR	LIPITOR	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
ATORVASTATIN	ATORVASTATIN	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
80	80	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Override	Override	NNP	I-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
2/12/06	2/12/06	CD	B-NP	O
by	by	IN	B-PP	O
SEVERSON	SEVERSON	NNP	B-NP	O
,	,	,	O	O
KASEY	KASEY	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
WARFARIN	WARFARIN	NN	B-NP	O
SODIUM	SODIUM	NN	I-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
463914335	463914335	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
ATORVASTATIN	ATORVASTATIN	NNP	B-NP	O
CALCIUM	CALCIUM	NNP	I-NP	O
&	&	CC	I-NP	O
WARFARIN	WARFARIN	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
ok	ok	VB	B-VP	O
CHOLESTYRAMINE	CHOLESTYRAMINE	NNP	B-NP	O
RESIN	RESIN	NNP	I-NP	O
DRIED	DRIED	NNP	I-NP	O
SUGAR	SUGAR	NNP	I-NP	O
FREE	FREE	NNP	I-NP	O
4	4	CD	I-NP	O
GM	GM	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
DOXAZOSIN	DOXAZOSIN	NNP	I-NP	O
4	4	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
HOLD	HOLD	NN	I-NP	O
IF	IF	NN	I-NP	O
:	:	:	O	O
sbp	sbp	NN	B-NP	O
<	<	SYM	O	O
100	100	CD	B-NP	O
HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE	NN	I-NP	O
12.5	12.5	CD	B-NP	O
MG	MG	NN	I-NP	O
+	+	SYM	B-NP	O
LOSARTAN	LOSARTAN	NN	B-NP	B-protein
50	50	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
1	1	CD	I-NP	I-protein
TAB	TAB	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
DAILY	DAILY	NN	I-NP	I-protein
HOLD	HOLD	NN	I-NP	I-protein
IF	IF	NN	I-NP	I-protein
:	:	:	O	O
sbp	sbp	NN	B-NP	O
<	<	SYM	O	O
100	100	CD	B-NP	O
Number	Number	NN	I-NP	O
of	of	IN	B-PP	O
Doses	Dose	NNS	B-NP	O
Required	Require	VBN	B-VP	O
-LRB-	-LRB-	HYPH	B-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
5	5	CD	B-NP	O
ZESTRIL	ZESTRIL	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
LISINOPRIL	LISINOPRIL	NN	I-NP	B-protein
-RRB-	-RRB-	HYPH	B-NP	I-protein
30	30	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
DAILY	DAILY	NN	I-NP	I-protein
HOLD	HOLD	NN	I-NP	I-protein
IF	IF	NN	I-NP	I-protein
:	:	:	O	O
sbp	sbp	NN	B-NP	O
<	<	SYM	O	O
100	100	CD	B-NP	O
LANTUS	LANTUS	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
INSULIN	INSULIN	NNP	I-NP	O
GLARGINE	GLARGINE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
10	10	CD	I-NP	O
UNITS	UNITS	NNP	I-NP	O
SC	SC	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
GLYBURIDE	GLYBURIDE	NNP	I-NP	O
10	10	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
ATENOLOL	ATENOLOL	NNP	I-NP	O
50	50	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
DIET	DIET	NNP	I-NP	O
:	:	:	O	O
House	House	NNP	B-NP	O
/	/	SYM	B-NP	O
Low	Low	JJ	I-NP	O
chol/low	chol/low	NN	I-NP	O
sat	sat	NN	I-NP	O
.	.	.	O	O

fat	fat	JJ	B-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NN	B-NP	O
/	/	SYM	O	O
ADA	ADA	NN	B-NP	O
2100	2100	CD	I-NP	O
cals/dy	cals/dy	NN	I-NP	O
ACTIVITY	ACTIVITY	NN	I-NP	O
:	:	:	O	O
Resume	Resume	VB	B-VP	O
regular	regular	JJ	B-NP	O
exercise	exercise	NN	I-NP	O
FOLLOW	FOLLOW	NNP	I-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
MHS	MHS	NNP	B-NP	O
Cardiology	Cardiology	NNP	I-NP	O
Clinic	Clinic	NNP	I-NP	O
:	:	:	O	O
:	:	:	O	O
Dr.	Dr.	NNP	B-NP	O
Jordan	Jordan	NNP	I-NP	O
Krupski	Krupski	NNP	I-NP	O
at	at	IN	B-PP	O
1PM	1PM	NN	B-NP	O
on	on	IN	B-PP	O
5/11/06	5/11/06	CD	B-NP	O
scheduled	schedule	VBN	B-VP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Mcquary	Mcquary	NNP	I-NP	O
within	within	IN	B-PP	O
1	1	CD	B-NP	O
week	week	NN	I-NP	O
for	for	IN	B-PP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
,	,	,	O	O
ALLERGY	ALLERGY	NN	B-NP	O
:	:	:	O	O
NKA	NKA	NN	B-NP	O
ADMIT	ADMIT	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
r/o	r/o	NN	B-NP	O
MI	MI	NNP	I-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NNP	B-NP	O
for	for	IN	B-PP	O
Causing	Causing	NNP	B-NP	O
Admission	Admission	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Musculoskeletal	Musculoskeletal	NNP	I-NP	O
pain	pain	NN	I-NP	O
OTHER	OTHER	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
dm	dm	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
diabetes	diabetes	NN	I-NP	O
mellitus	mellitus	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
htn	htn	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
hypertension	hypertension	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
hyperlipidemia	hyperlipidemia	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
hyperlipidemia	hyperlipidemia	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
gastric	gastric	JJ	I-NP	O
ulcer	ulcer	NN	I-NP	O
CAD	CAD	NN	I-NP	O
s/p	s/p	NN	I-NP	O
RCA	RCA	NN	I-NP	O
stent	stent	JJ	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
coronary	coronary	JJ	I-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
CRI	CRI	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
chronic	chronic	JJ	I-NP	O
renal	renal	JJ	I-NP	O
dysfunction	dysfunction	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
bph	bph	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
benign	benign	JJ	I-NP	O
prostatic	prostatic	JJ	I-NP	O
hypertrophy	hypertrophy	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
hearing	hearing	NN	I-NP	O
loss	loss	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
hearing	hearing	NN	I-NP	O
impairment	impairment	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
OPERATIONS	OPERATIONS	NNS	I-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNS	I-NP	O
:	:	:	O	O
none	none	NN	B-NP	O
.	.	.	O	O

OTHER	OTHER	NNP	B-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
none	none	NN	I-NP	O
.	.	.	O	O

BRIEF	BRIEF	NN	B-NP	O
RESUME	RESUME	NN	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
cc	cc	NN	B-NP	O
:	:	:	O	O
CP	CP	NN	B-NP	B-DNA
*****************************	*****************************	SYM	O	O
HPI	HPI	NN	B-NP	O
:	:	:	O	O
75M	75M	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
hx	hx	NN	I-NP	O
of	of	IN	B-PP	O
DM	DM	NN	B-NP	O
,	,	,	O	O
HTN	HTN	NN	B-NP	B-protein
,	,	,	O	O
Hchol	Hchol	NN	B-NP	O
,	,	,	O	O
recent	recent	JJ	B-NP	O
CVA	CVA	NN	I-NP	O
-LRB-	-LRB-	HYPH	O	O
4/06	4/06	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
Afib	Afib	NN	B-NP	O
,	,	,	O	O
CRI	CRI	NN	B-NP	B-protein
,	,	,	O	O
CAD/MI	CAD/MI	NN	B-NP	B-protein
s/p	s/p	NN	I-NP	I-protein
RCA	RCA	NN	I-NP	I-protein
stenting	stente	VBG	B-VP	O
-LRB-	-LRB-	SYM	B-NP	O
2002	2002	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
and	and	CC	O	O
poor	poor	JJ	B-NP	O
cardiac	cardiac	JJ	I-NP	O
f/up	f/up	NN	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Sarcinella	Sarcinella	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
p/w	p/w	NN	I-NP	O
CP	CP	NN	I-NP	O
.	.	.	O	O

States	State	NNS	B-NP	O
feeling	feel	VBG	B-VP	O
ok	ok	NN	B-NP	O
when	when	WRB	B-ADVP	O
awoke	awoke	NN	B-NP	O
this	this	DT	B-NP	O
AM	AM	NN	I-NP	O
.	.	.	O	O

Then	Then	RB	B-ADVP	O
had	have	VBD	B-VP	O
fleeting	fleeting	JJ	B-NP	O
substernal	substernal	JJ	I-NP	O
cp	cp	NN	I-NP	O
-LRB-	-LRB-	SYM	B-NP	O
30sec	30sec	CD	B-NP	O
-RRB-	-RRB-	SYM	I-NP	O
w/out	w/out	NN	I-NP	O
SOB	SOB	NN	I-NP	O
,	,	,	O	O
N/V/Radiation	N/V/Radiation	NN	B-NP	O
,	,	,	O	O
not	not	RB	B-PP	O
like	like	IN	I-PP	O
prior	prior	JJ	B-NP	O
CP	CP	NN	I-NP	B-DNA
.	.	.	O	O

Shortly	Shortly	RB	B-ADVP	O
after	after	IN	B-SBAR	O
had	have	VBD	B-VP	O
another	another	DT	B-NP	O
fleeting	fleeting	JJ	I-NP	O
episode	episode	NN	I-NP	O
.	.	.	O	O

Concerned	Concern	VBN	B-VP	O
came	come	VBD	B-VP	O
to	to	TO	B-PP	O
ED	ED	NNP	B-NP	O
where	where	WRB	B-ADVP	O
was	be	VBD	B-VP	O
pain	pain	NN	B-NP	O
free	free	JJ	B-ADJP	O
.	.	.	O	O

Given	Give	VBN	B-NP	O
ASA	ASA	NN	I-NP	B-protein
X	X	SYM	B-NP	I-protein
1	1	CD	I-NP	I-protein
.	.	.	O	O

Enzymes	Enzyme	NNS	B-NP	O
neg	neg	NN	I-NP	O
X1	X1	NN	I-NP	O
,	,	,	O	O
EKG	EKG	NN	B-NP	B-protein
w	w	NN	I-NP	I-protein
/	/	SYM	B-NP	O
bs	b	NNS	I-NP	O
line	line	NN	I-NP	O
abnormality	abnormality	NN	I-NP	O
but	but	CC	O	O
unchanged	unchanged	JJ	B-ADJP	O
.	.	.	O	O

Per	Per	IN	B-PP	O
outpt	outpt	JJ	B-NP	O
cardiologist	cardiologist	NN	I-NP	O
,	,	,	O	O
preffered	preffere	VBD	B-VP	O
admission	admission	NN	B-NP	O
to	to	TO	B-PP	O
WESWA	WESWA	NNP	B-NP	O
MEMORIAL	MEMORIAL	NNP	I-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
CENTER	CENTER	NNP	I-NP	O
team	team	NN	I-NP	O
for	for	IN	B-PP	O
R/O	R/O	NN	B-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O

CARDS	CARDS	NN	B-NP	O
:	:	:	O	O
Admitted	Admit	VBN	B-VP	O
for	for	IN	B-PP	O
R/O	R/O	NN	B-NP	O
.	.	.	O	O

While	While	IN	B-SBAR	O
presentation	presentation	NN	B-NP	O
not	not	RB	B-ADJP	O
suspicious	suspicious	JJ	I-ADJP	O
for	for	IN	B-PP	O
current	current	JJ	B-NP	O
cardiac	cardiac	JJ	I-NP	O
event	event	NN	I-NP	O
,	,	,	O	O
given	give	VBN	B-PP	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
cardiac	cardiac	JJ	B-NP	O
dz	dz	NN	I-NP	O
,	,	,	O	O
mulitple	mulitple	JJ	B-NP	B-protein
risk	risk	NN	I-NP	I-protein
factors	factor	NNS	I-NP	I-protein
and	and	CC	O	O
atypical	atypical	JJ	B-NP	O
presentations	presentation	NNS	I-NP	O
assoc	assoc	NN	I-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
dm	dm	NN	I-NP	O
,	,	,	O	O
reasonable	reasonable	JJ	B-ADJP	O
to	to	TO	B-PP	O
R/O	R/O	NN	B-NP	B-protein
.	.	.	O	O

Note	Note	RB	B-ADVP	O
,	,	,	O	O
Pt	Pt	NN	B-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
recent	recent	JJ	B-NP	O
negative	negative	JJ	I-NP	O
stress	stress	NN	I-NP	O
test	test	NN	I-NP	O
at	at	IN	B-PP	O
CJCGH	CJCGH	NN	B-NP	B-protein
,	,	,	O	O
though	though	IN	B-SBAR	O
limited	limited	JJ	B-NP	O
study	study	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
house	house	NN	B-NP	O
,	,	,	O	O
continued	continue	VBN	B-VP	O
on	on	IN	B-PP	O
ASA	ASA	NN	B-NP	O
,	,	,	O	O
BB	BB	NN	B-NP	B-protein
,	,	,	O	O
STATIN	STATIN	NN	B-NP	B-protein
,	,	,	O	O
ACE	ACE	NN	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
lipids	lipid	NNS	I-NP	O
were	be	VBD	B-VP	O
mildly	mildly	RB	I-VP	O
elevated	elevate	VBN	I-VP	O
with	with	IN	B-PP	O
LDL	LDL	NN	B-NP	O
80s	80	NNS	I-NP	O
,	,	,	O	O
though	though	RB	B-ADVP	O
already	already	RB	B-ADVP	O
on	on	IN	B-PP	O
Lipitor	Lipitor	NN	B-NP	O
80	80	CD	I-NP	O
and	and	CC	O	O
cholestyramine	cholestyramine	NN	B-NP	O
.	.	.	O	O

HGA1c	HGA1c	NN	B-NP	B-protein
was	be	VBD	B-VP	O
pending	pende	VBG	I-VP	O
at	at	IN	B-PP	O
time	time	NN	B-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
but	but	CC	O	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
as	as	IN	B-SBAR	O
outpatient	outpatient	NN	B-NP	O
to	to	TO	B-VP	O
ensure	ensure	VB	I-VP	O
good	good	JJ	B-NP	O
DM	DM	NN	I-NP	O
control	control	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
Pt	Pt	NN	B-NP	B-protein
had	have	VBD	B-VP	I-protein
HR	HR	NN	B-NP	I-protein
to	to	TO	B-PP	O
the	the	DT	B-NP	O
40	40	CD	I-NP	O
's	's	POS	B-NP	O
inhouse	inhouse	NN	I-NP	O
,	,	,	O	O
though	though	IN	B-SBAR	O
asymptomatic	asymptomatic	JJ	B-ADJP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
lopressor	lopressor	NN	B-NP	O
while	while	IN	B-SBAR	O
observed	observe	VBN	B-VP	O
and	and	CC	O	O
transitioned	transitione	VBN	B-VP	O
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Atenolol	Atenolol	NN	B-NP	O
50qd	50qd	CD	I-NP	O
which	which	WDT	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
a	a	DT	B-NP	O
stable	stable	JJ	I-NP	O
,	,	,	I-NP	O
asymptomatic	asymptomatic	JJ	I-NP	O
dose	dose	NN	I-NP	O
.	.	.	O	O

Given	Give	VBN	B-VP	O
extremely	extremely	RB	B-NP	O
low	low	JJ	I-NP	O
risk	risk	NN	I-NP	O
presentation	presentation	NN	I-NP	O
and	and	CC	I-NP	O
r/o	r/o	NN	I-NP	O
,	,	,	O	O
pt	pt	NN	B-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
following	follow	VBG	B-PP	O
morning	morning	NN	B-NP	O
for	for	IN	B-PP	O
outpatient	outpatient	NN	B-NP	O
follow	follow	VBP	B-VP	O
up	up	RP	B-PRT	O
.	.	.	O	O

If	If	IN	B-SBAR	O
a	a	DT	B-NP	O
repeat	repeat	NN	I-NP	O
imaging	imaging	NN	I-NP	O
is	be	VBZ	B-VP	O
performed	perform	VBN	I-VP	O
,	,	,	O	O
may	may	MD	B-VP	O
reccomend	reccomend	VB	I-VP	O
for	for	IN	B-PP	O
chemical	chemical	JJ	B-NP	O
stress	stress	NN	I-NP	O
study	study	NN	I-NP	O
as	as	IN	B-PP	O
prior	prior	JJ	B-NP	O
stress	stress	NN	I-NP	O
limited	limit	VBN	B-VP	O
.	.	.	O	O

Should	Should	MD	B-VP	O
note	note	VB	I-VP	O
that	that	DT	B-NP	O
EKG	EKG	NN	I-NP	B-protein
had	have	VBD	B-VP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
significant	significant	JJ	B-NP	O
LVH	LVH	NN	I-NP	O
and	and	CC	I-NP	O
repol	repol	NN	I-NP	O
abnormality	abnormality	NN	I-NP	O
corroberated	corroberate	VBN	B-VP	O
with	with	IN	B-PP	O
recent	recent	JJ	B-NP	O
echo	echo	NN	I-NP	O
.	.	.	O	O

Would	Would	MD	B-VP	O
continue	continue	VB	I-VP	O
to	to	TO	I-VP	O
assess	assess	VB	I-VP	O
for	for	IN	B-PP	O
possible	possible	JJ	B-NP	O
hypertrophic	hypertrophic	JJ	I-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
along	along	IN	B-PP	O
with	with	IN	B-PP	O
familial	familial	JJ	B-NP	O
risk	risk	NN	I-NP	O
assessment	assessment	NN	I-NP	O
as	as	IN	B-PP	O
outpatient	outpatient	NN	B-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
also	also	RB	B-ADVP	O
w	w	NN	B-NP	O
/	/	SYM	I-NP	O
hx	hx	NN	I-NP	O
of	of	IN	B-PP	O
Parox	Parox	NNP	B-NP	O
Afib	Afib	NNP	I-NP	O
,	,	,	O	O
now	now	RB	B-ADVP	O
in	in	IN	B-PP	O
sinus	sinus	NN	B-NP	O
and	and	CC	O	O
recent	recent	JJ	B-NP	O
stroke	stroke	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
rate	rate	NN	I-NP	O
was	be	VBD	B-VP	O
well	well	RB	I-VP	O
cotnrolled	cotnrolle	VBN	I-VP	O
in	in	IN	B-PP	O
house	house	NN	B-NP	O
on	on	IN	B-PP	O
BB	BB	NNP	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
INR	INR	NN	B-NP	B-protein
was	be	VBD	B-VP	O
3.2	3.2	CD	B-NP	O
and	and	CC	O	O
warfarin	warfarin	NN	B-NP	O
dose	dose	NN	I-NP	O
reduced	reduce	VBD	B-VP	O
to	to	TO	I-VP	O
2mg	2mg	VB	I-VP	O
-LRB-	-LRB-	NN	B-NP	B-protein
from	from	IN	B-PP	O
4mg	4mg	NN	B-NP	B-protein
-RRB-	-RRB-	NN	I-NP	I-protein
.	.	.	O	O

On	On	IN	B-PP	O
following	follow	VBG	B-PP	O
day	day	NN	B-NP	O
,	,	,	O	O
INR	INR	NN	B-NP	B-protein
3.4	3.4	CD	I-NP	I-protein
.	.	.	O	O

Pt	Pt	NN	B-NP	O
instructed	instruct	VBN	B-VP	O
to	to	TO	I-VP	O
hold	hold	VB	I-VP	O
dose	dose	NN	B-NP	O
that	that	IN	B-NP	O
evening	evening	NN	B-NP	O
and	and	CC	O	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
in	in	IN	B-PP	O
coumadin	coumadin	NN	B-NP	O
clinic	clinic	NN	I-NP	O
on	on	IN	B-PP	O
2/22/06	2/22/06	CD	B-NP	O
.	.	.	O	O

ADDITIONAL	ADDITIONAL	JJ	B-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O
-RRB-	-RRB-	NNP	B-NP	O

Continue	Continue	JJ	B-NP	O
medications	medication	NNS	I-NP	O
as	as	IN	B-SBAR	O
directed	direct	VBN	B-VP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O
-RRB-	-RRB-	NNP	B-NP	O

If	If	IN	B-SBAR	O
fleeting	fleeting	JJ	B-NP	O
episodes	episode	NNS	I-NP	O
of	of	IN	B-PP	O
pain	pain	NN	B-NP	O
recur	recur	VBP	B-VP	O
,	,	,	O	O
would	would	MD	B-VP	O
not	not	RB	I-VP	O
worry	worry	VB	I-VP	O
-LRB-	-LRB-	NN	B-NP	B-protein
though	though	IN	B-SBAR	O
notify	notify	JJ	B-NP	O
PCP/caridologist	PCP/caridologist	NN	I-NP	O
if	if	IN	B-SBAR	O
severe	severe	JJ	B-NP	O
,	,	,	I-NP	O
perisistant	perisistant	JJ	I-NP	O
,	,	,	I-NP	O
or	or	CC	I-NP	O
associated	associate	VBN	I-NP	O
w	w	NN	I-NP	O
/	/	SYM	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
prior	prior	JJ	B-NP	O
heart	heart	NN	I-NP	O
attack	attack	NN	I-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

Can	Can	MD	B-VP	O
use	use	VB	I-VP	O
motrin	motrin	NN	B-NP	O
for	for	IN	B-PP	O
occasional	occasional	JJ	B-NP	B-protein
pains	pain	NNS	I-NP	I-protein
.	.	.	O	O

3	3	CD	B-NP	O
.	.	.	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O

Follow	Follow	VB	B-VP	O
up	up	RP	B-PRT	O
w	w	NN	B-NP	O
/	/	SYM	B-VP	O
Dr.	Dr.	NNP	B-NP	O
Sterling	Sterling	NNP	I-NP	O
Wegweiser	Wegweiser	NNP	I-NP	O
in	in	IN	B-PP	O
V	V	NNP	B-NP	O
cardiology	cardiology	NN	I-NP	O
clinic	clinic	NN	I-NP	O
as	as	IN	B-SBAR	O
scheduled	schedule	VBN	B-VP	O
.	.	.	O	O

4	4	CD	B-NP	O
.	.	.	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O

Follow	Follow	VB	B-VP	O
up	up	RP	B-PRT	O
w	w	NN	B-NP	O
/	/	SYM	B-VP	O
Dr.	Dr.	NNP	B-NP	O
Royal	Royal	NNP	I-NP	O
with	with	IN	B-PP	O
in	in	IN	B-PP	O
one	one	CD	B-NP	O
week	week	NN	I-NP	O
re	re	NN	I-NP	O
:	:	:	O	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
on	on	IN	B-PP	O
oral	oral	JJ	B-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-NP	O
TO	TO	NN	I-NP	O
DO/PLAN	DO/PLAN	NN	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O

Titrate	Titrate	NN	B-NP	O
meds	med	NNS	I-NP	O
as	as	IN	B-PP	O
outpatient	outpatient	NN	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O
-RRB-	-RRB-	NNP	B-NP	O

Consider	Consider	VB	B-VP	O
outpatient	outpatient	NN	B-NP	O
cardiac	cardiac	JJ	I-NP	O
imaging	imaging	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
last	last	JJ	B-NP	O
done	done	NN	I-NP	O
2005	2005	CD	B-NP	O
at	at	IN	B-PP	O
FM	FM	NNP	B-NP	O
,	,	,	O	O
but	but	CC	O	O
limited	limited	JJ	B-NP	O
study	study	NN	I-NP	O
--	--	:	O	O
consider	consider	VB	B-VP	O
chemical	chemical	JJ	B-NP	B-protein
stress	stress	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O
-RRB-	-RRB-	NNP	B-NP	O

Follow	Follow	VB	B-VP	O
up	up	RP	B-PRT	O
re	re	NN	B-NP	O
:	:	:	O	O
Peri-oral	Peri-oral	JJ	B-NP	O
lesions	lesion	NNS	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Konopka	Konopka	NNP	I-NP	O
.	.	.	O	O

4	4	CD	B-NP	O
.	.	.	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O

Follow	Follow	NNP	B-NP	O
INR	INR	NNP	I-NP	O
at	at	IN	B-PP	O
Coumadin	Coumadin	NNP	B-NP	O
Clinic	Clinic	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Note	Note	NNP	I-NP	O
,	,	,	O	O
Held	Held	NNP	B-NP	O
on	on	IN	B-PP	O
D/C	D/C	NNP	B-NP	O
and	and	CC	O	O
scheduled	schedule	VBN	B-VP	O
for	for	IN	B-PP	O
check	check	NN	B-NP	O
2/22/06	2/22/06	CD	I-NP	O
No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
DOBROSKY	DOBROSKY	NNP	B-NP	O
,	,	,	O	O
DAMON	DAMON	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
OL26	OL26	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
8/19/06	8/19/06	CD	I-NP	O
@	@	NN	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
12	12	CD	B-NP	O
PM	PM	NN	I-NP	O
******	******	SYM	B-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

